Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based..

Journal

Leuk Lymphoma, 2024

Authors

Kim JL, Gerrie AS, Savage KJ, Villa D, Scott D, Craig JW, Farinha P, Skinnider B, Slack G, Connors JM, Sehn LH, Venner C, Freeman CL

Learn More

BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.

Donate Today

Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based..

BC Cancer Research

Office of Research Administration

Population Health Sciences

Genome Sciences Centre

Terry Fox Laboratory

Molecular Oncology

Integrative Oncology

Lymphoid Cancer Research

Experimental Therapeutics

Clinical Research

Deeley Research Centre